Transthyretin Amyloidosis (ATTR) Serum

About Transthyretin Amyloidosis (ATTR) Serum

Transthyretin Amyloidosis (ATTR) Serum for Amyloid and Cardiac Biomarker Research

Our Transthyretin Amyloidosis (ATTR) Serum is sourced from IRB-consented donors clinically diagnosed with ATTR amyloidosis, a progressive disease in which misfolded transthyretin (TTR) protein aggregates into amyloid fibrils that deposit in peripheral nerves and the heart. Each sample is processed and frozen within 24 hours of collection to preserve circulating TTR, cardiac biomarkers, and other amyloid-relevant proteins.

ATTR Biology and Why Serum

• ATTR amyloidosis arises from destabilized TTR tetramers – either due to inherited point mutations (hereditary/variant ATTR, ATTRv) or age-related misfolding of wild-type TTR (ATTRwt) – that dissociate into monomers prone to aggregation and fibril formation.
• Amyloid deposition in peripheral and autonomic nerves produces a length-dependent polyneuropathy, while cardiac deposition causes restrictive cardiomyopathy with progressive heart failure and conduction abnormalities.
• Serum is widely used for TTR concentration and stability immunoassays and is the standard matrix for many clinical cardiac biomarker platforms (NT-proBNP, high-sensitivity troponin) that track amyloid cardiomyopathy severity.
• Approved and investigational therapeutics target distinct mechanisms: TTR tetramer stabilizers (e.g. tafamidis), TTR gene-silencing therapies (patisiran, inotersen, vutrisiran), and CRISPR-based knockdown approaches, all of which rely on circulating TTR level and stability measurements for pharmacodynamic monitoring.
• Genotype (e.g. Val142Ile, Val50Met) and phenotype (predominantly neuropathic, cardiac, or mixed) are key stratification variables for both natural history and treatment-response research.

Donor Stratification Available

• ATTR subtype: hereditary/variant (ATTRv) versus wild-type (ATTRwt)
• TTR genotype where known
• Predominant phenotype: neuropathic, cardiac, or mixed
• Disease stage and polyneuropathy disability score where available
• Treatment history, including TTR stabilizers or gene-silencing therapies
• Age band and sex assigned at birth
• Matched healthy controls available

Product Features

• Collected from clinically confirmed ATTR amyloidosis donors
• Processed and frozen within 24 hours of collection
• Research Use Only (RUO)
• IRB-approved protocols with documented consent
• Standard and custom aliquot volumes available

De-identified Donor Data

• ATTR diagnosis confirmation and genotype where documented
• Age, sex assigned at birth, and ethnicity
• Donor-reported allergy and infectious disease history
• ATTR subtype, phenotype, and treatment history where documented
• Additional ATTR-specific metadata available on request

Applications

• TTR stability and tetramer-kinetic stabilization assay development
• Cardiac biomarker profiling (NT-proBNP, high-sensitivity troponin) in amyloid cardiomyopathy
• Pharmacodynamic monitoring for TTR stabilizers and gene-silencing therapeutics
• Biomarker discovery for early detection and disease progression
• Genotype-phenotype correlation studies

Other Transthyretin Amyloidosis Specimen Types

• Transthyretin Amyloidosis (ATTR) Plasma

Compliance and Quality Assurance

• IRB-approved and HIPAA-compliant protocols
• Electronic informed consent with 21 CFR Part 11-compliant e-signatures
• Documentation support available for regulatory review

Ordering & Customization

Transthyretin amyloidosis serum is available in standard and custom volumes. For pricing, international orders, or documentation requirements, please email learnmore@sanguinebio.com to ensure compatibility with your country’s regulations. To compare donor availability across conditions, visit our human serum page.